Pharma的新Bcl-2抑制剂Lisaftoclax获得中国血液癌治疗优先审查。 Ascentage Pharma's new Bcl-2 inhibitor, Lisaftoclax, gains Priority Review in China for treating blood cancers.

亚盛药业的新型Bcl-2抑制剂Lisaftoclax已被接受在中国进行优先审查,用于治疗复发性或耐药性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤. Ascentage Pharma's novel Bcl-2 inhibitor, Lisaftoclax, has been accepted for Priority Review in China for treating relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. 这是中国国内开发的第一种Bcl-2抑制剂,如果得到批准,可以是全球核准的第二种此类药物。 This is China's first domestically developed Bcl-2 inhibitor and, if approved, could be the second such drug approved globally. 该药物正在各种癌症的多种第三阶段研究中进行测试。 The drug is being tested in multiple phase III studies for various cancers.